IOL Chemicals and Pharmaceuticals Limited is an innovation-driven company specializing in bulk drugs, intermediates, and specialty chemicals, known for its extensive manufacturing capacities and diverse product portfolio. Established in 1986, IOLCP is one of India's leading generic pharmaceutical companies and a significant player in the Organic chemicals space. The company has built a strong reputation in the pharmaceutical and chemical industries through its commitment to quality, innovation, and customer service.
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and a significant player in the specialty chemicals sector. It serves both the domestic and export markets, operating through two main business verticals: Active Pharmaceutical Ingredients (APIs) and Specialty Chemicals, serving diverse markets across the globe.
The company operates through two primary business verticals that have established it as a significant player in both the pharmaceutical and chemical industries.
Through its well-established API vertical, IOLCP develops and provides various essential products used by pharma companies across the world to make key medicines. IOLCP has a wide presence across various therapeutic categories like Pain Management, Anti-diabetic, Anti-hypertensive, Anti-convulsants, etc.
The company has achieved remarkable market leadership in key pharmaceutical ingredients. It is the largest manufacturer of Ibuprofen globally with a world market share of 35% and a leading manufacturer of Metformin and Ethyl Acetate. This dominant position in the global Ibuprofen market demonstrates the company's manufacturing excellence and competitive advantages.
Under its chemicals division, IOLCP produces Ethyl Acetate from organic alcohol for use in a variety of end products in markets, including flexible packaging, pharmaceuticals, textiles, food processing, pesticides, and paint industries.
The company has established strong manufacturing capabilities in specialty chemicals. It is the largest producer of Ethyl Acetate at a single location in India and also the 2nd largest producer of Iso Butyl Benzene (IBB) with approximately 30% global share. In the last three decades, IOLCP has made an indelible mark as one of the leading manufacturers of the 'green chemical' Ethyl Acetate across the globe.
As of the latest available data, IOL Chemicals & Pharmaceuticals Ltd has a market capitalization of ₹2,840 crore. The company's financial performance reflects both challenges and strengths in the current market environment.
For the fiscal year 2025, net profit declined 24.82% to ₹101.07 crore compared to ₹134.43 crore during the previous year ended March 2024. Sales declined 2.51% to ₹2,079.21 crore in the year ended March 2025, against ₹2,132.79 crore during the previous year ended March 2024.
However, the company showed improvement in the fourth quarter of FY25. Net profit of IOL Chemicals & Pharmaceuticals rose 13.76% to ₹31.42 crore in the quarter ended March 2025, as against ₹27.62 crore during the previous quarter ended March 2024. Sales rose 4.73% to ₹527.78 crore in the quarter ended March 2025, against ₹503.92 crore during the previous quarter ended March 2024.
- Market Capitalization: ₹2,840 Crore (as of latest available data)
- Annual Revenue (FY25): ₹2,079.21 crore
- Annual Net Profit (FY25): ₹101.07 crore
- Promoter Holding: 52.62% (as of Mar 2025)
- Debt Position: Company is almost debt-free
The company's success is built on strong operational foundations and manufacturing capabilities. IOL Chemicals and Pharmaceuticals Limited, incorporated in September 1986, is a renowned company in the Active Pharmaceutical Ingredient (API) and specialty chemicals sectors. With substantive manufacturing capacities, the Company benefits from economies of scale and cost supremacy.
As one of the leading specialty chemical manufacturing companies across the world, IOLCP has built a reputation for maintaining the highest GMP standards and quality. IOL Chemicals and Pharmaceuticals Limited adopts the most stringent protocols to monitor and ensure high-quality products and services reach its customers.
Innovation remains at the core of the company's strategy. Its R&D efforts concentrate on developing products that intend to solve the needs of the pharmaceutical industry in terms of uninterrupted supply of superior quality products. This focus on research and development enables the company to maintain its competitive edge and develop new products to meet evolving market demands.
The company maintains strong corporate governance practices with a balanced shareholding structure. Promoter holding in IOL Chemicals & Pharmaceuticals Ltd has gone up to 52.62% as of Mar 2025 from 48.19% as of Jun 2024. This increase in promoter holding indicates management's confidence in the company's future prospects.
The company has been active in rewarding shareholders through dividends. IOL Chemicals & Pharmaceuticals has fixed 18 February 2025 as the record date for an interim dividend of ₹4 per share for FY 2024-25. The Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, recommended the interim dividend of ₹4 per equity share (i.e., 40%).
The company has also undertaken a stock split initiative to improve accessibility. Accordingly, the face value of each share of the company will change to ₹2, which is one-fifth of its present face value of ₹10. The company expects to complete the stock split proposal within a period of two months from the date of shareholder's approval. The split of equity shares will make the shares more affordable, thereby increasing its attractiveness to a wider range of investors.
IOL Chemicals & Pharmaceuticals Limited continues to leverage its manufacturing excellence, market leadership in key products, and strong operational capabilities to navigate industry challenges while maintaining its position as a leading player in both pharmaceutical APIs and specialty chemicals sectors.
